JAHA: β受体阻滞剂可致左心功能受损?

2017-04-21 phylis MedSci原创

背景:高血压患者左心房(LA)机械功能受损,并可能导致各种并发症,包括房性心律失常,卒中和心脏衰竭。不同降压药物对中枢血流动力学和左室功能的影响不同。然而它们对LA功能的影响的了解较少。方法:研究者研究212例高血压患者,这些患者无心脏衰竭或房颤。根据心脏稳态自由进洞序列MRI影像学,应用特征跟踪算法计算LA应变率。结果:在多变量模型中,校正年龄、性别、种族、体重指数、血压、糖尿病、LA体积,左心

背景:高血压患者左心房(LA)机械功能受损,并可能导致各种并发症,包括房性心律失常,卒中和心脏衰竭。不同降压药物对中枢血流动力学和左室功能的影响不同。然而它们对LA功能的影响的了解较少。

方法:研究者研究212例高血压患者,这些患者无心脏衰竭或房颤。根据心脏稳态自由进洞序列MRI影像学,应用特征跟踪算法计算LA应变率。

结果:在多变量模型中,校正年龄、性别、种族、体重指数、血压、糖尿病、LA体积,左心室肥厚,左心室射血分数后,应用β-受体阻滞剂与总纵向应变(标准化β= -0.21;P = 0.008)和LA扩张指数(标准化β= -0.30;P<0.001)较低相关,提示LA储备功能受损。β-受体阻滞剂的应用也与低应变(标准化β= -0.19;P = 0.012)和舒张早期峰值应变率(标准化β= 0.15;P = 0.039)呈正相关,表明LA管道功能受损。最后,使用β受体阻滞剂与舒张晚期应变率较低(标准化β= 0.15;P = 0.049),应变率(标准化β= 0.18;P = 0.019)及LA排空分数(标准化β= -0.27;P<0.001)较低相关,提示泵功能受损。其他抗高血压药物的使用与LA功能不相关。

结论:β受体阻滞剂的使用与高血压患者LA功能受损显著相关。这种相关性可以解释使用β-受体阻滞剂(与其他抗高血压药物相比)的患者心房颤动和卒中风险增加。

原文出处:

Sardana M, Syed AA, et al. Beta-Blocker Use Is Associated With Impaired Left Atrial Function in Hypertension. J Am Heart Assoc. 2017 Feb 3


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-06-19 zhyy88
  2. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-23 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-23 内外兼修

    已学习,谢谢分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2085748, encodeId=cd752085e4834, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Mon Jun 19 09:34:00 CST 2017, time=2017-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995143, encodeId=2165199514319, content=<a href='/topic/show?id=347538040cf' target=_blank style='color:#2F92EE;'>#受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38040, encryptionId=347538040cf, topicName=受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Mar 20 03:34:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1267418, encodeId=95b9126e4183e, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274947, encodeId=f96c12e494749, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19228, encryptionId=338c19228b0, topicName=β受体阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465660, encodeId=055a1465660de, content=<a href='/topic/show?id=5f5f508933f' target=_blank style='color:#2F92EE;'>#心功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50893, encryptionId=5f5f508933f, topicName=心功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6df96750284, createdName=caobinglei8081, createdTime=Sun Apr 23 08:34:00 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189814, encodeId=0e3b189814e5, content=已学习,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLPONqEZIpjBMOqJ99CtjQaSGgoDXJzlMPusdPuBLX1qvETANlKzogXmibR2V3VKyczicDTGqaX3h1R/0, createdBy=93301959502, createdName=内外兼修, createdTime=Sun Apr 23 07:50:22 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189423, encodeId=6edf189423f2, content=这可能是对beta阻滞剂重要的打击, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 20:05:17 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 lovetcm

    这可能是对beta阻滞剂重要的打击

    0

相关资讯

Sci Rep:终末期肾脏疾病患者可应用β受体阻滞剂预防房颤发生

目前的证据表明,β受体阻滞剂降低心脏手术后房颤(AF)和卒中发生的风险。本研究的目的是评估β受体阻滞剂是否能降低终末期肾脏疾病(ESRD)患者新发房颤的发生。研究者从灾难性疾病患者记录这个全国性的数据库确定1995到2008的患者,这些患者几乎100%接受透析治疗。应用倾向得分和Cox比例风险回归模型评估新发房颤的危险比(HR)。在100066例患者中,41.7%接受β受体阻滞剂。随访中位数为15

Heart:长QT综合征孕妇心律失常风险及β-受体阻滞剂治疗分析!

LQTS高危患者的早期诊断和β受体阻滞剂治疗是妊娠期间和产后心脏事件预防的重要手段,在LQT-P患者中,胎儿可能可以耐受β-受体阻滞剂治疗。

JAHA:接受非心脏手术的糖尿病患者到底该怎样服用β受体阻滞剂?

术前30天以上服用心脏保护性β受体阻滞剂才能减少死亡率风险,而短期服用β受体阻滞剂与糖尿病患者死亡率的差异无关。

BMJ:早期使用β受体阻滞剂可降低急性心肌梗死患者30天死亡率

本研究旨在评估早期和长期β受体阻滞剂治疗与急性心肌梗死后死亡率之间的关系. 多中心前瞻性队列研究设计纳入2005年前法国全国急性ST和非ST段抬高心肌梗死(FAST-MI)登记册的患者(223个中心)。 研究最终纳入2679例急性心肌梗死,但无心力衰竭或左室功能不全的患者。 结果,77%(2050 / 2679)的患者早期使用β受体阻滞剂,80%(1783 / 2217)的患者出院时

BMJ:β受体阻滞剂治疗射血分数减少的心衰患者,不受年龄和性别的影响

该研究的目的是通过汇集来自安慰剂对照随机试验中个体患者的数据来确定在射血分数减少(HFrEF)的心脏衰竭广泛年龄段的女性和男性患者中,β受体阻滞剂的疗效和耐受性。原始出处:Dipak Kotecha,Luis Manzano,Henry Krum,et al.Effect of age and sex on efficacy and tolerability of β blockers in pa

Chest:治疗脓毒症期间房颤——β受体阻滞剂优于CCBs

脓毒症期间发生房颤(AF)增加发病率和死亡率,但在脓毒症期间有针对性的治疗AF心率和节律的实践模式和结果目前还不清楚。该项回顾性队列研究的数据来自于约20%的美国医院。研究人员确定了脓毒症期间IV级AF治疗的相关因素(β受体阻滞剂[BBs],钙通道阻滞剂[CCBs],地高辛,或胺碘酮)。研究人员使用倾向得分匹配和工具变量的方法来比较不同治疗房颤方法之间的死亡率。在39693例脓毒症期间发生房颤的患